Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | JAK1 | P23458 | 4/20 | 0.52 |
| ▸ | TYK2 | P29597 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6194819 | 0.93 | USP30 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL2324285 | 0.93 | USP30 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL4513756 | 0.88 | JAK2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL27035789 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL25291831 | 0.81 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL672317 | 0.80 | TMEM97 (0.49) | SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL13246605 | 0.80 | TMEM97 (0.49) | SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4521587 | 0.80 | TMEM97 (0.49) | SMN1; SMN2NPC1RAB9ANPSR1 | |
| SCHEMBL4035554 | 0.79 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 | |
| SCHEMBL18005739 | 0.78 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3929203-A1 | DERIVATIVES OF AMPHOTERICIN B | Sfunga Therapeutics, Inc. (US) | 2021-12-29 | — | — | EP | disclosed |
| EP-3283171-B1 | DERIVATIVES OF AMPHOTERICIN B | SFUNGA THERAPEUTICS INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10882883-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | ELION THERAPEUTICS, INC. | 2020-08-20 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957290-B2 | Derivatives of amphotericin B | SFUNGA THERAPEUTICS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2791139-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-11-08 | — | — | EP | disclosed |
| EP-2791139-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr Reddys Laboratories Ltd (IN) | 2017-11-08 | — | — | EP | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304548-A1 | Derivatives of Amphotericin B | ELION THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2015-01-01 | — | — | US | disclosed |
| EP-2791139-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | Dr. Reddy's Laboratories Ltd. (IN) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| WO-2013088257-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2013-06-20 | — | — | WO | disclosed |
| US-8399681-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | BIGNAN GILLES (US) | 2012-11-29 | — | — | US | disclosed |
| EP-2513096-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-A MODULATORS | Janssen Pharmaceutica, N.V. (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-8263781-B2 | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-11 | — | — | US | disclosed |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075565-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-Aα MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005280-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS | NTRK1, MUSK, NTRK3 | SMN1; SMN2 1521/4885NPC1 3182/4885RAB9A 1861/4885 |
| US-20160304548-A1 | Derivatives of Amphotericin B | C9, ERG28, AMPD3 | SMN1; SMN2 4528/4885NPC1 173/4885RAB9A 1090/4885 |
| US-20120302544-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | SMN1; SMN2 3292/4885NPC1 3010/4885RAB9A 3063/4885 |
| US-10882883-B2 | Derivatives of amphotericin B | C9, ERG28, AMPD3 | SMN1; SMN2 4528/4885NPC1 173/4885RAB9A 1090/4885 |
| US-20200262858-A1 | DERIVATIVES OF AMPHOTERICIN B | C9, ERG28, AMPD3 | SMN1; SMN2 4528/4885NPC1 173/4885RAB9A 1090/4885 |
| US-20110150864-A1 | SUBSTITUTED AMINOTHIAZOLONE INDAZOLES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS | ESR2, ESRRA, IGF1R | SMN1; SMN2 3292/4885NPC1 3010/4885RAB9A 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.